RITALIN LA Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Ritalin La, and what generic alternatives are available?

Ritalin La is a drug marketed by Sandoz and is included in one NDA.

The generic ingredient in RITALIN LA is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ritalin La

A generic version of RITALIN LA was approved as methylphenidate hydrochloride by SPECGX LLC on November 27^th, 1998.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for RITALIN LA?
What are the global sales for RITALIN LA?
What is Average Wholesale Price for RITALIN LA?

Summary for RITALIN LA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	126
Patent Applications:	3,514
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for RITALIN LA
Drug Sales Revenues:	Drug sales revenues for RITALIN LA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RITALIN LA
DailyMed Link:	RITALIN LA at DailyMed

Drug patent expirations by year for RITALIN LA

Recent Clinical Trials for RITALIN LA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Johns Hopkins University	Phase 4
University of Florida	Early Phase 1
University of Zurich	Phase 1

See all RITALIN LA clinical trials

Pharmacology for RITALIN LA

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Paragraph IV (Patent) Challenges for RITALIN LA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RITALIN LA	Extended-release Capsules	methylphenidate hydrochloride	10 mg	021284	1	2007-05-21
RITALIN LA	Extended-release Capsules	methylphenidate hydrochloride	20 mg, 30 mg and 40 mg	021284		2006-08-21

US Patents and Regulatory Information for RITALIN LA

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	RITALIN LA	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021284-004	Apr 10, 2004	AB1	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Sandoz	RITALIN LA	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021284-003	Jun 5, 2002	AB1	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Sandoz	RITALIN LA	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021284-001	Jun 5, 2002	AB1	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for RITALIN LA

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	RITALIN LA	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021284-002	Jun 5, 2002	⤷ Sign Up	⤷ Sign Up
Sandoz	RITALIN LA	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021284-001	Jun 5, 2002	⤷ Sign Up	⤷ Sign Up
Sandoz	RITALIN LA	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021284-001	Jun 5, 2002	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for RITALIN LA

See the table below for patents covering RITALIN LA around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Eurasian Patent Organization	200701195		⤷ Sign Up
New Zealand	503571	Chronic, bolus administration of D-threo methylphenidate	⤷ Sign Up
Austria	368458		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration